Intech Biopharm Statistics

Total Valuation

Intech Biopharm has a market cap or net worth of TWD 3.66 billion. The enterprise value is 4.76 billion.

Market Cap	3.66B
Enterprise Value	4.76B

Important Dates

The next estimated earnings date is Thursday, March 13, 2025.

Earnings Date	Mar 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Intech Biopharm has 137.94 million shares outstanding. The number of shares has increased by 16.46% in one year.

Current Share Class	n/a
Shares Outstanding	137.94M
Shares Change (YoY)	+16.46%
Shares Change (QoQ)	+0.17%
Owned by Insiders (%)	1.26%
Owned by Institutions (%)	1.92%
Float	74.65M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	105.65
PB Ratio	4.01
P/TBV Ratio	4.04
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-13.16
EV / Sales	139.67
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-14.82

Financial Position

The company has a current ratio of 1.31, with a Debt / Equity ratio of 1.58.

Current Ratio	1.31
Quick Ratio	0.95
Debt / Equity	1.58
Debt / EBITDA	n/a
Debt / FCF	-4.47
Interest Coverage	-10.13

Financial Efficiency

Return on equity (ROE) is -42.40% and return on invested capital (ROIC) is -9.28%.

Return on Equity (ROE)	-42.40%
Return on Assets (ROA)	-8.84%
Return on Capital (ROIC)	-9.28%
Revenue Per Employee	415,512
Profits Per Employee	-4.41M
Employee Count	82
Asset Turnover	0.01
Inventory Turnover	4.12

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -5.04% in the last 52 weeks. The beta is 0.32, so Intech Biopharm's price volatility has been lower than the market average.

Beta (5Y)	0.32
52-Week Price Change	-5.04%
50-Day Moving Average	27.84
200-Day Moving Average	28.36
Relative Strength Index (RSI)	38.60
Average Volume (20 Days)	73,698

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Intech Biopharm had revenue of TWD 34.07 million and -361.71 million in losses. Loss per share was -2.67.

Revenue	34.07M
Gross Profit	-160.51M
Operating Income	-345.97M
Pretax Income	-361.71M
Net Income	-361.71M
EBITDA	-260.22M
EBIT	-345.97M
Loss Per Share	-2.67

Full Income Statement

Balance Sheet

The company has 333.88 million in cash and 1.44 billion in debt, giving a net cash position of -1.10 billion or -8.00 per share.

Cash & Cash Equivalents	333.88M
Total Debt	1.44B
Net Cash	-1.10B
Net Cash Per Share	-8.00
Equity (Book Value)	908.82M
Book Value Per Share	6.61
Working Capital	112.55M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -276.95 million and capital expenditures -44.22 million, giving a free cash flow of -321.17 million.

Operating Cash Flow	-276.95M
Capital Expenditures	-44.22M
Free Cash Flow	-321.17M
FCF Per Share	-2.33

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-1,015.40%
Pretax Margin	-1,061.60%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Intech Biopharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.46%
Shareholder Yield	-16.46%
Earnings Yield	-10.08%
FCF Yield	-8.79%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Intech Biopharm has an Altman Z-Score of 0.78. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.78
Piotroski F-Score	n/a